Comparative Pharmacology
Head-to-head clinical analysis: DROSPIRENONE ETHINYL ESTRADIOL AND LEVOMEFOLATE CALCIUM versus NATURAL ESTROGENIC SUBSTANCE ESTRONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DROSPIRENONE ETHINYL ESTRADIOL AND LEVOMEFOLATE CALCIUM versus NATURAL ESTROGENIC SUBSTANCE ESTRONE.
DROSPIRENONE, ETHINYL ESTRADIOL AND LEVOMEFOLATE CALCIUM vs NATURAL ESTROGENIC SUBSTANCE-ESTRONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of drospirenone (a progestin with antimineralocorticoid and antiandrogenic activity), ethinyl estradiol (an estrogen), and levomefolate calcium (a folate supplement). Prevents ovulation by suppressing gonadotropins; increases cervical mucus viscosity, inhibiting sperm penetration; levomefolate provides folate to reduce neural tube defect risk.
Estrone binds to and activates estrogen receptors (ERα and ERβ), leading to modulation of gene transcription and subsequent estrogenic effects on target tissues.
One tablet orally once daily for 28 days (21 active tablets containing drospirenone 3 mg, ethinyl estradiol 0.02 mg, and levomefolate calcium 0.451 mg, followed by 7 placebo tablets containing levomefolate calcium 0.451 mg).
0.1 to 0.5 mg intramuscularly 2 to 3 times per week for estrogen replacement therapy
None Documented
None Documented
Drospirenone: ~30 hours (steady state achieved after 8 days). Ethinyl estradiol: ~13-17 hours (biphasic, terminal). Levomefolate calcium: ~4-6 hours (folate derivatives have longer retention).
Terminal half-life: 24-48 hours (prolonged due to enterohepatic recirculation and tissue distribution).
Drospirenone: ~50% renal (as metabolites), ~40% fecal. Ethinyl estradiol: ~40% renal, ~60% fecal. Levomefolate calcium: ~70% renal (as folate metabolites), ~30% fecal.
Renal: ~50% (as glucuronide and sulfate conjugates), Biliary/Fecal: ~50% (enterohepatic recirculation).
Category D/X
Category C
Progestin + Estrogen
Estrogen